Long-Term Safety Study of KW-6002 (Istradefylline) in Parkinson's Disease Patients
Launched by KYOWA KIRIN CO., LTD. · Aug 11, 2009
Trial Information
Current as of May 16, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Be willing and able to give written informed consent
- • 2. Completion of the study 6002-009
- Exclusion Criteria:
- • 1. Mini-mental status examination score of 23 or less
- • 2. Less than 70% of compliance in the study 6002-009
- • 3. Emergency deviation in the study 6002-009
- • 4. Pregnant females
About Kyowa Kirin Co., Ltd.
Kyowa Kirin Co., Ltd. is a global pharmaceutical company headquartered in Japan, dedicated to the discovery, development, and commercialization of innovative therapies to address unmet medical needs. With a strong emphasis on biotechnology, the company focuses on areas such as oncology, nephrology, and immunology, leveraging advanced research and development capabilities to enhance patient outcomes. Kyowa Kirin is committed to ethical practices and collaboration in clinical trials, ensuring the highest standards of safety and efficacy in its therapeutic offerings. Through its dedication to scientific excellence and patient-centric approaches, Kyowa Kirin strives to improve the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tokyo, , Japan
Patients applied
Trial Officials
Study Director
Study Director
Kyowa Kirin Co., Ltd.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials